Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of rotenone in preparing medicine for treating diabetic nephropathy

A technology for diabetic nephropathy and rotenone, which is applied in the field of application of rotenone in the preparation of drugs for diabetic nephropathy, and can solve problems such as differences in treatment methods

Inactive Publication Date: 2018-09-14
NANJING CHILDRENS HOSPITAL
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Diabetic nephropathy is a kind of chronic kidney disease, but its pathogenesis is different from other chronic secondary kidney diseases, and the treatment methods are also different
There is no report on the use of rotenone in the treatment of diabetic nephropathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of rotenone in preparing medicine for treating diabetic nephropathy
  • Application of rotenone in preparing medicine for treating diabetic nephropathy
  • Application of rotenone in preparing medicine for treating diabetic nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The safety evaluation of embodiment 1 low-dose rotenone (100ppm is mixed and taken in feed)

[0029] 1 Experimental materials

[0030] The C57BL / 6 species mice used in the present invention were purchased from the Experimental Animal Center of Nanjing Medical University;

[0031] The present invention uses rotenone (Rotenone, ROT) purchased from Sigma-Aldrich Company. 100ppm rotenone feed (100mg rotenone was uniformly mixed into 400kg feed powder, mixed with 600mL agar powder aqueous solution (2%, m / v) sugar to form); the feed used by the mice in the control group was a drug-free feed prepared in the same way.

[0032] 2 Experimental methods

[0033] 2.1 Animal administration method

[0034] Thirty male C57BL / 6 mice (7 weeks old, body weight 20-24g) were fed adaptively for 1 week and randomly divided into Ctrl group (n=7) and ROT group (n=7). Before the experiment, the animals had free access to food and maintained a circadian rhythm of 12 hours of light and 12 hour...

Embodiment 2

[0039] Example 2 Rotenone Improves Diuretic Symptoms, Increased Kidney Weight and Glomerular Hypertrophy in Diabetic Nephropathy Mice

[0040] 1 Experimental materials

[0041] Streptozocin (STZ) and sodium citrate used in the present invention were purchased from Sigma-Aldrich Company. STZ is dissolved in sodium citrate solution (pH=4.0), ready for immediate use. Other biological materials and chemical materials are the same as in Example 1.

[0042] 2 Experimental methods

[0043] 2.1 Establishment of mouse diabetic nephropathy model and administration method of rotenone

[0044] Thirty male C57BL / 6 mice (7 weeks old, body weight 20-24g) were fed adaptively for 1 week and then underwent unilateral nephrectomy. The specific method is: take a midline incision in the abdomen of the mouse, cut the muscle layer along the linea alba, enter the abdominal cavity, push the intestinal tube to the opposite side, expose the kidney and blood vessels on one side, fully free the blood ...

Embodiment 3

[0052] Example 3 Rotenone improves the level of kidney damage in mice with diabetic nephropathy

[0053] 1 Experimental materials

[0054] The urine microalbumin detection kit used in the present invention was purchased from Bethyl Laboratories; other biological materials and chemical materials were the same as in Example 1.

[0055] 2 Experimental methods

[0056] 2.1 Serum biochemical detection

[0057] Whole blood samples from mice in each group were collected, left at room temperature for 1-2 hours, centrifuged at 4000rpm for 10 minutes, and the supernatant was transferred to obtain serum samples for determination of serum creatinine (Cr) and blood urea nitrogen (BUN) levels.

[0058] 2.2 Detection of urinary microalbumin

[0059] Take the urine of the mice in each group at the 4th week after the start of treatment in the STZ+ROT group, dilute it according to urine:PBS=1:200, and perform quantitative detection according to the instructions.

[0060] 24h urinary microal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention aims to provide application of rotenone in preparing a medicine for treating diabetic nephropathy to provide a novel candidate compound for treating diabetic nephropathy. Experimental results show that rotenone of a selected dosage has no liver, kidney and heart toxicity; hyperuresis of diabetic nephropathy model mice can be remarkably alleviated, and kidney weight increase, glomerular hypertrophy, impaired renal function, microalbuminuria increase, kidney metabolic disorders and renal fibrosis, caused by STZ, of the mice are reversed.

Description

technical field [0001] The invention relates to the application of rotenone in the preparation of medicines, in particular to the application of rotenone in the preparation of diabetic nephropathy medicines. technical background [0002] With the development of social economy and the change of people's lifestyle, the incidence of diabetes is increasing year by year. According to reports, there were 92 million diabetic patients in China in 2008, and it reached 114 million in 2013, and the number of pre-diabetic patients reached 150 million. There are 264 million abnormal people. Diabetic nephropathy (Diabetic Nephropathy, DN) is one of the microvascular complications of diabetic patients, and has become the second factor leading to end-stage renal disease. [0003] Common clinical secondary kidney diseases include acute kidney injury and chronic kidney disease. Acute kidney injury refers to acute renal tubular injury caused by drugs, poisons, or renal tissue ischemia; while...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61P13/12A61P3/10
CPCA61K31/352A61P3/10A61P13/12
Inventor 张爱华吴梦秋贾占军张玥陈维宜麻昊阳
Owner NANJING CHILDRENS HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com